Pulsatile MAPK Signaling Modulates P53 Activity to Control Cell Fate Decisions at the G2 Checkpoint for DNA Damage
Overview
Cell Biology
Molecular Biology
Affiliations
Cell-autonomous changes in p53 expression govern the duration and outcome of cell-cycle arrest at the G2 checkpoint for DNA damage. Here, we report that mitogen-activated protein kinase (MAPK) signaling integrates extracellular cues with p53 dynamics to determine cell fate at the G2 checkpoint. Optogenetic tools and quantitative cell biochemistry reveal transient oscillations in MAPK activity dependent on ataxia-telangiectasia-mutated kinase after DNA damage. MAPK inhibition alters p53 dynamics and p53-dependent gene expression after checkpoint enforcement, prolonging G2 arrest. In contrast, sustained MAPK signaling induces the phosphorylation of CDC25C, and consequently, the accumulation of pro-mitotic kinases, thereby relaxing checkpoint stringency and permitting cells to evade prolonged G2 arrest and senescence induction. We propose a model in which this MAPK-mediated mechanism integrates extracellular cues with cell-autonomous p53-mediated signals, to safeguard genomic integrity during tissue proliferation. Early steps in oncogene-driven carcinogenesis may imbalance this tumor-suppressive mechanism to trigger genome instability.
Decoding SFRP2 progenitors in sustaining tooth growth at single-cell resolution.
Zhao T, Zhong Q, Sun Z, Yu X, Sun T, An Z Stem Cell Res Ther. 2025; 16(1):58.
PMID: 39920788 PMC: 11806734. DOI: 10.1186/s13287-025-04190-z.
UCHL1 Overexpression Is Related to the Aggressive Phenotype of Non-small Cell Lung Cancer.
Kim C, Lee E, Kwak S, Lee S, Kim E, Park M Tuberc Respir Dis (Seoul). 2024; 87(4):494-504.
PMID: 39362830 PMC: 11468449. DOI: 10.4046/trd.2023.0166.
HER2 Antibody-Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor.
Zhang T, Febres-Aldana C, Liu Z, Dix J, Cheng R, Dematteo R Clin Cancer Res. 2024; 30(20):4701-4713.
PMID: 39120576 PMC: 11479846. DOI: 10.1158/1078-0432.CCR-24-1835.
B-Myb deficiency boosts bortezomib-induced immunogenic cell death in colorectal cancer.
Hui Y, Yu T, Li L, Peng X, Di M, Liu H Sci Rep. 2024; 14(1):7733.
PMID: 38565963 PMC: 10987531. DOI: 10.1038/s41598-024-58424-w.
Wu C, Song D, Chen Z, Hu C, Lin D, Chang H Biology (Basel). 2024; 13(3).
PMID: 38534403 PMC: 10968125. DOI: 10.3390/biology13030133.